Scarica l'app Stockscreener
0.781
1.20%
-0.0095
Pre-mercato:
.78
-0.001
-0.13%
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics expands board, appoints new director - Investing.com India
Check Out Seres Therapeutics Inc (MCRB)’s Trade Data Rather Than the Analysts’ Views - SETE News
Seres Therapeutics Expands Board with Nestlé’s Appointee - TipRanks
Recent Insider Activity Suggests Potential Gains for Seres Therapeutics Inc (MCRB) - Knox Daily
A year in review: Seres Therapeutics Inc (MCRB)’s performance in the last year - US Post News
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
**Seres Therapeutics, Inc. Posts Updated Corporate Presentation – 8-K Filing Review**** - Defense World
Seres Therapeutics receives $50 million from Nestlé Health Science By Investing.com - Investing.com Australia
Seres Therapeutics receives $50 million from Nestlé Health Science - MSN
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - The Manila Times
Seres Therapeutics Receives $50M Payment from Nestlé, Extends Cash Runway to 2026 - StockTitan
Seres Therapeutics Strengthens Future with VOWST Sale - TipRanks
Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World
Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World
StockNews.com Downgrades Seres Therapeutics (NASDAQ:MCRB) to Sell - MarketBeat
Seres announces new translational biomarker results from SER-155 Phase 1b study - Yahoo Finance
Geode Capital Management LLC Acquires 255,014 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates - The Manila Times
Seres Therapeutics Announces New Translational Biomarker - GlobeNewswire
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows - StockTitan
State Street Corp Purchases 43,700 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - Defense World
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat
5 Best Microbiome Companies (January 2025) - Securities.io
The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable - Yahoo Finance
Charles Schwab Investment Management Inc. Has $708,000 Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference - Yahoo Finance
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - citybiz
Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference - The Manila Times
Seres Therapeutics' Breakthrough Therapy Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders - The Eastern Progress Online
Seres’ SER-155 gains breakthrough status for BSIs reduction - Yahoo Finance
MCRBSeres Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - The Manila Times
FDA Grants Breakthrough Therapy Designation to Seres - GlobeNewswire
Seres' SER-155 Wins FDA Breakthrough Status After Stunning 77% Infection Reduction in Transplant Study - StockTitan
Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times
Seres Therapeutics CEO to Present at Piper Sandler Healthcare Conference | MCRB Stock News - StockTitan
Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com Nigeria
0.82%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):